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Background: Investigations of genetic alterations and correlations with histology or morphology could provide
further insights into colorectal carcinogenesis. Nevertheless, such genetic changes were less investigated in
adenoma stage and a comprehensive survey of oncogenic mutations in EGFR signaling pathway according to
different morphologic subtypes has not been performed.
Methods: A total of 94 neoplasms, including 34 polypoid adenoma, 16 lateral spreading tumors-granular (LST-G),
20 non-granular LST (LST-NG), and 24 depressed tumors, were subjected for mutational analysis of KRAS (exon 2),
BRAF (exon 11 and 15), PIK3CA (exon 9 and 20), AKT (exon 4), EGFR (exon 18–24) and HER2 (exon18-24).
Results: KRAS mutation was noted more frequently in LST (13/36, 36.1%) than polypoid neoplasms (5/34, 14.7%,
p = 0.041). When comparing with LST-NG, LST-G had a significantly higher frequency of KRAS mutation. (9/16,
56.3% vs. 4/20, 20.0%, p = 0.024). BRAF mutation (V600E) was found in 2 of 36 (5.6%)LSTs and 1 of 34 (2.9%)
polypoid lesions. The two LST lesions with BRAF mutation were pathologically proven to be serrated adenoma. PIK3CA
mutation (exon 9 E545K) was identified only in LST (5/36, 13.9%). Mutations in KRAS, BRAF or PIK3CA occurred in a
mutually exclusive manner. All mutations were absent in the specimens obtained from depressed type neoplasms.
Conclusions: Three different macroscopic subtypes of colorectal neoplasms display distinct carcinogenetic pathways
in EGFR networking. Further molecular studies of CRCs should take macroscopic subtypes into consideration and
highlight the importance of consensus and communication between endoscopic and pathologic diagnosis.
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Colorectal cancer (CRC) is the most frequent malig-
nancy of gastrointestinal tract. With respect to patho-
genesis and therapeutic responses, CRC is regarded as a
heterogenous disease. Macroscopically, CRC can be clas-
sified into polypoid and nonpolypoid subtypes [1]. The
latter usually presents as flat or depressed tumors and is
further subcategorized into depressed type, flat tumor
less than 1.0 cm (0-IIa) and laterally spreading tumor
(LST). Among nonpolypoid variants, depressed subtypes
have the most aggressive behavior and represent the* Correspondence: mingshiang@ntu.edu.tw
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unless otherwise stated.main lesions of de novo pathway [2-7]. Such variants are
more difficult to identify by endoscopy and initially re-
ported only in Japan. However, with the advance of
image enhanced endoscopic techniques, the incidence
of non-polypoid neoplasms has been rising and now
accounts for 20-30% of CRC [7,8]. The unique clinico-
pathologic characteristics and biological behaviors for
different macroscopic morphology suggest that distinct
carcinogenetic pathways might exist for various subtypes
of CRC.
The classic adenoma-carcinoma sequence of CRC was
defined on histologic grounds and had been the corner-
stone of current screening, surveillance and prevention.
Polypoid adenoma is the main precursor lesion in such
classical pathways. Serial genetic changes in APC, KRAS,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Investigations of genetic alterations and correlations with
histology or morphology could provide further insights
into colorectal carcinogenesis. A recent example is the
identification of oncogenic mutation of BRAF in serrated
pathway [10]. Furthermore, a better understanding of the
molecular mechanisms underlying the development of
different CRCs would open the way for patient-specific
therapy. This is reflected in the current practice that anti-
epidermal growth factor receptor antibody therapy is no
longer offered to CRC patients with mutant KRAS [11].
Moreover, nevertheless the fecal DNA testing was devel-
oped to detect significant neoplastic lesions, the precise
genetic change of nonpolypoid neoplasm remains elusive
and therefore such neoplasms may be missed by these
tests [12]. Collectively, elucidation of genetic mechanisms
by which these alterations affect colorectal carcinogenesis
might have a profound impact on more effective strategies
for screening, diagnosis and treatment of CRCs [13,14].
Epidermal growth factor receptor (EGFR) signaling in-
fluences multiple downstream pathways, including Ras/
Raf/MAPK and phosphatidylinositol 3’-kinase (PI3K)/
AKT pathways. Alterations of signaling in this pathway
had been reported to affect cell proliferation, survival
and apoptosis of a variety of malignancies [14]. A sub-
stantial portion of CRC was observed to harbor non-
overlapping somatic mutations of KRAS, BRAF, PIK3CA
and AKT genes [15-23]. Nevertheless, such genetic
changes were less investigated in adenoma stage and a
comprehensive survey of oncogenic mutations in EGFR
signaling pathway according to different morphologic
subtypes has not been performed. In this study, we aimed
to assess the frequency and distribution of EGFR pathway
alterations in three subtypes of colorectal neoplasms.
Some subcategories of 0-IIa lesions, the so called laterally
spreading tumor (LST), extend laterally and circumferen-
tially rather than vertically along the colonic wall and the
frequency of invasive carcinoma is known to be less than
that of polypoid lesions with similar size [14,15]. Though
it is classified as “non-polypoid” neoplasm as a whole
with depressed lesions recently, its clinicopathological
characteristics are distinct from depressed (0-IIc) or flat
and depressed (0-IIa + IIc or 0-IIc + IIa) lesions [6,7].
LSTs are considered as less invasive as they rarely be-
come invasive till the size of 3 cm or more [6,15]. Among
LSTs, granular type (LST-G) and flat type (LST-NG) are
also different. Malignant transformation is more com-
mon in LST-NG at smaller size with higher risk of multi-
focal submucoal invasion in comparison with LST-G
[15]. Some different genetic alterations were also ob-
served between polypoid, LST-G and LST-NG [16,17].
Therefore, it is reasonable to speculate a unique bio-
logical behavior or molecular basis of malignant trans-
formation in such non-polypoid neoplasms.Among different phenotypes of LST, granular type and
flat type were reported to have different frequency of
KRAS mutation and other genetic or epigenetic changes
[16,17]. However, concurrent analysis of KRAS and BRAF
mutation for such lesions has never been conducted be-
fore. In this study, we aim to elucidate the frequency of
KRAS mutation and BRAF mutation in polypoid, flat and
depressed colorectal neoplasms and compare these mor-
phological counterparts each other.
Methods
Patient samples
The study protocol was approved by institutional review
board of National Taiwan University Hospital, and
informed consent was obtained from all patients. We
prospectively recruited 85 patients who underwent endo-
scopic or surgical resection of colorectal neoplasms from
September 2006 to December 2008. The endoscopic
morphology of colorectal tumors was mainly based on
Paris and Japanese Research Society classifications with
some modifications of subtypes as we have described else-
where [1]. Lesions with 0-Is or 0-Ip were classified into
“protruded” subtype (Figure 1, A & B). LSTs were defined
as lesions ≥10 mm in diameter with a low vertical axis ex-
tending laterally along the interior luminal wall. They were
further subdivided into granular (LST-G) or nongranular
(LST-NG) subtypes according to macroscopic findings:
LST-G has even or uneven nodules on the surface whereas
LST-NG type has a smooth surface (Figure 1, C & D). Le-
sions categorized as 0-IIc, 0-IIc + IIa or 0-IIa + IIc were de-
pressed subtype (Figure 1, E & F). A total of 94 neoplasms
were subjected for further analyses. These included 34
polypoid subtype, 36 LSTs (16 LST-G, 20 LST-NG), and
24 depressed subtype.
Histopathological assessment
Hematoxylin and eosin stained slides prepared from rou-
tinely processed paraffin-embedded tissue samples were
assessed. The histopathological analysis of each tumor
was done according to the WHO criteria [24]. Advanced
colorectal neoplasia was defined as those lesions with
one of the following criteria: lesions larger than 10 mm
in diameter, lesions with a villous component, high-grade
dysplastic (HGD) lesions or carcinoma in situ (CIS), and
lesions with invasive features. All specimens were reviewed
by the same pathologist (Chia-Tung Shun), who was un-
aware of the colonoscopic findings, medical history and
the results of genetic analysis.
DNA extraction
DNA was extracted from surgical or endoscopic speci-
mens. Briefly, tumor cell-rich areas in 0.1% methylene
blue-stained 10-μm sections under microscopy were
scratched with 20 gauge needles and deparaffinized.
Figure 1 Macroscopic classification of colorectal neoplasm. A: 0-Ip, B: 0-Is, C: LST-G, D: LST-NG, E: 0-IIa + IIc, F: 0-IIc.
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reaction (PCR) buffer containing proteinase K solution.
After heat inactivation, the extracted DNAs were subjected
for sequencing analyses.
Mutation analyses
Intron-based PCR primers were used to amplify the tar-
geted exons of KRAS, BRAF, HER2, EGFR, PIK3CA and
AKT genes based on previously published sequences. The
primers were as follows (forward and reverse, respectively):
BRAF exon 11 (5’-TTCTGTTTGGCTTGACTTGACTT-
3’ and 5’-ACTTGT CACAATGTCACCTT-3’) and exon
15 (5’-TGCTTGCTCTGATAGGAAAAT G-3’ and 5’-AGCATCTCAGGGCCAAAAAT-3’); [23] KRAS exon 2 (5’-
CTGAAAATGACTGAATATAAACTTGT-3’ and 5’-ATA
TGCATATTAAAACAA GATTTACC-3’); [24] AKT exon
4 (5’-CACACCCAGTTCCTGCCT-3’ and 5’-CCTGGTG
GGCAAAGAGGGCT-3’); [25] PIK3CA exon 9 (5’-TCAG
CAGTTACTATTCTGTGACTGG-3’ and 5’-GTAAAAC
GACGGCCAGTTGCTGAGATCAGCCAAATTCA-3’)
and exon 20 (5’-GTAAAACGACGGCCAGTGACATTT
GAGCAAAGACCTGAAG-3’ and 5’-TGGATTGTGCA
ATTCCTATGC-3’); [26] EGFR exon 18 (5’-AGCATGGT
GAGGGCTGAGGTGAC-3’ and 5’-ATATACAGCTTG
CAAGGACTCTGG-3’), exon 19 (5’-CCAGATCACTGG
GCAGCATGTGGCACC-3’ and 5’-AGCAGGGTCTAG
Table 1 Basic demographic characteristics of studied
colorectal neoplasms
Polypoid LST-G LST-NG Depressed
Lesion no./patient no. 34/26 16/15 20/20 24/24
Gender(M/F) 18/8 6/9 15/5 21/3
Mean age 61.0 67.7 64.9 61.3
Proximal/distal 16/18 13/3 16/4 12/12
Mean size ± SD (cm) 1.58 2.21 1.99 0.89
Histopathology
HGD 0 2 4 3
CIS 0 2 3 0
Invasive cancer 0 2 3 3
HGD: high-grade dysplasia; CIS: carcinoma in situ.
Table 2 Mutation rates in different macroscopic subtypes
of colorectal neoplasms
Mutation LST(%)(n = 36) Polypoid(%)(n = 34) Depressed(%)(n = 24)
KRAS 13/36 (36.1%) 5/34 (14.7%) 0/24 (0%)
BRAF 2/36 (5.6%) 1/24 (2.9%) 0/24 (0%)
PIK3CA 5/36 (13.9%) 0/34 (0%) 0/24 (0%)
AKT 0/36 (0%) 0/34 (0%) 0/24 (0%)
EGFR 0/36 (0%) 0/34 (0%) 0/24 (0%)
HER2 0/36 (0%) 0/34 (0%) 0/24 (0%)
Chang et al. BMC Gastroenterology  (2014) 14:1197 Page 4 of 8AGCAGAGCAGCTGCC-3’), exon 20 (5’-GATCGCAT
TCATGCGTCTTCACC-3’ and 5’-TTGCTATCCCAGG
AGCGCAGACC-3’), exon 21 (5’-TCAGAGCCTGGCA
TGAACATGACCCTG-3’ and 5’-GGTCCCTGGTGTCA
GGAAAATGCTGG-3’), exon 22 (5’-AATTAGGTCCA
GAGTGAGTTAAC-3’ and 5’-ACTTGCATGTCAGAG
GATATAATG-3’), exon 23 (5’-CATCAAGAAACAGT
AACCAGTAATG-3’ and 5’-AAGGCCTCAGCTGTTT
GGCTAAG-3’), exon 24 (5’-TTGACTGGAAGTGTCG
CATCACC-3’ and 5’-CATGTGACAGAACACAGTGA
CATG-3’); [27] HER2 exon 18 (5’-GTGAAGTCCTCC
CAGCCCGC-3’ and 5’-CTCCCATCAGAACTGCCGA
CC-3’), exon 19 (5’-TGGAGGACAAGTAATGATCTCC
TGG-3’ and 5’-AAGAGAGACCAGAGCCCAGACCTG-
3’), exon 20 (5’-GCCATGGCTGTGGTTTGTGATGG-3’
and 5’-ATCCTAGCCCCTTGTGGACATAGG-3’), exon
21 (5’-GGACTCTTGCTGGGCATGTGG-3’ and 5’-CC
ACTCAGAGTTCTCCCATGG-3’), exon 22 (5’-CCATG
GGAGAACTCTGAGTGG-3’ and 5’-TCCCTTCACATG
AGGTGG-3’), exon 23 (5’-AGACTCCTGAGCAGAAC
CTCTG-3’ and 5’-AGCCAGCACAGCTCAGCCAC-3’),
and exon 24 (5’-ACTGTCTAGACCAGACTGGAGG-3’
and 5’-GAGGGTGCTCTTAGCCACAGG-3’) [28]. PCR
was performed in a 20-μl volume containing 100 ng of
template DNA, 10 × PCR buffer; 0.25 mM deoxynucleo-
side triphosphate (dNTP), 20 pmol primers, and 1.5 U
Taq DNA polymerase (Takara Shuzo, Kyoto, Japan).
PCR products were electrophoresed on 2% agarose gels,
purified, and both strands were directly sequenced
using the BigDye Terminator v3.1 cycle sequencing kit,
followed by analysis with an Applied Biosystems 3700
automated sequencer (Applied Biosystems, Foster City,
CA, USA). All suspected mutations were confirmed by
independent PCR amplifications and sequenced in both
directions.
Statistical methods
Statistical analysis was done using SAS program (version
9.1, Cary, NC, U.S.A.). Noncontinuous variables were
analyzed with chi-square test or Fischer’s exact test as
indicated. Continuous variables were analyzed using
two-sided t tests.
Results
Demographic and clinicopathological characteristics of
polypoid, LST and depressed neoplasms
A total of 94 colorectal neoplasms were collected from
85 patients, including 34 polypoid lesions, 36 LST and
24 depressed lesions. Table 1 lists the demographic and
clinicopathologic characteristics according to macro-
scopic subtypes. There was no significant difference
in age and gender distribution. A higher percentage
of proximal location was noted for LSTs. The tumor
size was relatively smaller for depressed lesions. Severehistological changes such as high-grade dysplasia, carcin-
oma in situ and invasive cancer were not noted for polyp-
oid tumors.
Mutational analyses in polypoid, LST and depressed
neoplasms
The mutational profile of all the specimens is summa-
rized in Table 2. There was no mutation identified for
EGFR, HER2 and AKT genes. KRAS mutation (codon 2)
was noted more frequently in LST (13/36, 36.1%) than
polypoid neoplasms (5/34, 14.7%, p = 0.041). When com-
paring LST-G with LST-NG, LST-G had a significantly
higher frequency of KRAS mutation than in LST-NG.
(9/16, 56.3% vs. 4/20, 20.0%, p = 0.024). BRAF mutation
(V600E) was found in 2 of 36 (5.6%) LSTs and 1 of 34
(2.9%) polypoid lesions (Table 3). The two LST lesions
with BRAF mutation were macroscopically classified as
granular type and pathologically proven to be serrated
adenoma (Figure 2). In contrast, the polypoid tumor
with BRAF mutation was confirmed as traditional ser-
rated adenoma. PIK3CA mutation (exon 9 E545K) was
identified only in LST (5/36, 13.9%). Mutations in KRAS,
BRAF or PIK3CA occurred in a mutually exclusive man-
ner. All mutations were absent in the specimens obtained
from depressed type neoplasms.
Table 3 Comparison of BRAF mutation in lesions with
different macroscopic types
Morphology BRAF (+) BRAF (−) p-value
Polypoid (n = 34) 1* 33 1.00
LST (n = 36) 2* 34
Depressed (n = 24) 0 24 -
*Pathologically turned out to have serrated change.
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A wealth of data has revealed CRCs defined by distinct
molecular and pathologic features correspond with dif-
fering responses to particular chemotherapy and clinical
outcomes. The increasing recognition of distinct clinico-
pathologic behaviors between polypoid and non-polypoid
colorectal polyps had added to the need for clarification of
molecular pathogenesis of these different subtypes of neo-
plasm. The current study represents the first comprehen-
sive and concurrent analysis of activation mutations in
EGFR network. We found flat lesions, especially granular
type LST, displayed a higher frequency of KRAS and
PIK3CA mutations as compared to those of polypoid tu-
mors. Furthermore, no mutations were detected in de-
pressed tumors, indicating existence of different molecular
pathways for these clinically more aggressive lesions. OurFigure 2 A case of BRAF positive LST-G. A and B: Conventional view an
(LST-G) lesion. C: NBI with magnifying observation revealed no obvious capfindings support the notion that different macroscopic
colorectal polyps may have distinct pathogenesis.
KRAS is a GTPase protein that is activated by EGFR
and other cell surface growth factor receptors and acti-
vation of EGFR/KRAS/BRAF pathway plays a key role in
the carcinogenesis of several malignancies. Mutations in
KRAS can be identified in 30-40% of colorectal cancers
[13,14] and mutated KRAS is constitutively active inde-
pendent of EGFR signaling. The presence of a KRAS
mutation may predict lack of response to EGFR inhibi-
tors in metastatic CRC [11,13,14]. In this study, we dem-
onstrated that frequency of KRAS mutation was higher
in LST-G than in LST-NG or polypid tumors. These
findings were in agreement with the study of Sugimoto
and colleagues [29]. In their study, they found LST-G
displayed more frequent KRAS mutations and LST-NG
had more nuclear accumulation of beta-catenin and ex-
pression of MYC. Similar observations of higher muta-
tion rate of KRAS in LST-G have also been documented
by Hiraoka and Mukawa et al. [30,31] The KRAS muta-
tion in LST-G may vary according to different neoplasm
location. Kaji et al. have reported that LST-G in the
proximal colon was significantly associated with KRAS
mutation [32]. Our study failed to analyze the mutation
in distinct-morphology neoplasm with different locationd chromoendoscopy dye-spraying with indigo-carmine revealed 0-IIa
illary mesh. D: Magnifying observation revealed type II pit pattern.
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our study. Collectively, subtypes of LST could have dif-
ferent molecular characteristics. Because LST in general
could be detected in earlier stage and resected by endos-
copy, whether these tumors, when become advanced,
might have different responses to treatment remains to
be further investigated.
BRAF is a downstream molecule of KRAS and muta-
tion of BRAF V600E was detected in 5-10% of CRC
[20,23]. Tumors with BRAF mutation are microsatellite
instable, predominantly located in proximal colon, aris-
ing from serrated adenoma and have poor prognosis and
unsatisfactory response to EGFR inhibitor [20,24,33]. In
this study, we found two cases in LST and one case in
polypoid tumors displayed BRAF mutations. Reevalua-
tion of their pathology revealed they belonged to sessile
serrated adenoma and traditional serrated adenoma re-
spectively. Serrated pathway has recently been con-
sidered a separate one from traditional adenoma-
adenocarcinoma pathway because of their characteristic
flat appearance and distinct molecular alterations. These
tumors were more frequently overlooked by endosco-
pists than traditional adenomas and regarded as an im-
portant cause of interval cancer [34-36]. The increasing
complexity of macroscopic and histologic classification
of colorectal polyps suggested communications and con-
sensus between endoscopists and pathologists are crucial
for further investigation of molecule profiles of CRCs.
The PIK3CA gene encodes a lipid kinase regulating
signaling pathway downstream of the EGFR alongside
with KRAS. Mutations of PIK3CA occurred in 15-20%
of CRC and were associated with poor prognosis among
curative resected CRCs [17,22]. The role of PIK3 muta-
tions in determining EGFR inhibitor remains controver-
sial. Two different reports showed discrepant results
[18,21]. In contrast to CRC, the data of PIK3CA muta-
tions in colorectal polyps remained few. Velho et al. have
demonstrated one of 17 (5.6%) colorectal polyps had
PIK3CA mutation [16]. However, no macroscopic classi-
fication was mentioned in their study. In our study, we
found PIK3CA mutations occurred predominantly in
LST. Our results reemphasized the importance of macro-
scopic subtyping in the investigation of genetic alterations
of colorectal neoplasm.
Depressed colorectal lesions, in contrast to polypoid
tumors, tended to develop high-grade dysplasia or sub-
mucosal invasive cancer when they were small. The
aggressive behavior and characteristic morphology sug-
gested that they may follow a different carcinogenic path-
way to flat elevated or protruding adenomas. Compared
to more and more endoscopic and clinicopathologic re-
searches for depressed colorectal tumors, investigations of
genetic alterations remain scanty [37,38]. Previous studies
for these tumors showed no mutations in KRAS and highfrequencies of p53 expression by immunohistochemistry
[37]. Through PCR-based pyrosequencing, Konda et al.
have reported that mutation in KRAS and BRAF occurred
in 16% and 11% of depressed colorectal neoplasms re-
spectively [39]. There was a discrepancy between this
study and ours. In our study, we did not find any unique
genetic changes regarding EGFR network, including KRAS
and BRAF, in depressed colorectal neoplasms. This dis-
crepancy may be attributed to low tumor content among
our depressed colorectal neoplasms. The lower tumor
content may lead to higher false negative result. Moreover,
only 3 HGD and 3 T1 cancers occurred in our total 24
depressed colorectal neoplasms. In study conducted by
Konda et al., all the 19 depressed lesions harbored HGD
or invasive cancers. Therefore, the more advanced hist-
ology may contribute to more genetic alterations. Finally,
the sample size in both studies was limited. Only 3 and 2
depressed colorectal neoplasms had mutations in KRAS
and BRAF respectively. Further researches with larger
sample size and in a multi-center setting are mandatory to
elucidate the relevant genetic or epigenetic changes of this
special subset of CRCs.
The investigation of genetic alterations in relation to
different macroscopic subtypes may also provide new in-
sights into CRC screening. Previous studies in this field
have reported the usefulness of stool DNA testing in ex-
perimental settings but only modest or unsatisfactory
sensitivity for cancer and advanced adenoma were ob-
served in population-based study [40]. Superficial neo-
plasms, including fat and depressed lesions, are good
candidates for the target of screening and endoscopic
treatment because it remains non-invasive until fairly
large size [7,41]. Development of molecular probe with
combination of variable molecular marker is an at-
tractive field which may enable detection of such a
flat neoplasm much easier [42]. Several studies have used
fluorescently labeled antibodies against epitopes that are
commonly overexpressed in most GI cancers, such as vas-
cular endothelial growth factor or epidermal growth factor
receptor (EGFR) [43]. If such probe for superficial colorec-
tal neoplasm is developed, it will be of great help for im-
proving detectability during colonoscopy. To make this
scenario fulfilled, elucidations of molecular pathogenesis
in different subtypes of CRC are crucial.
In summary, our findings provide further insights into
the genetic alterations of colorectal neoplasms with re-
spect to distinct macroscopic morphology. The muta-
tional profile of KRAS, and PIK3CA in LSTs is different
from protruded lesions and different subtypes of LSTs
display distinct mutations. LST-G with BRAF mutation
is more likely to be a sessile serrated adenoma. No spe-
cific activating mutation in EGFR network is observed in
the depressed lesions although these tumors behave more
aggressive than protruded adenomas and LSTs. Further
Chang et al. BMC Gastroenterology  (2014) 14:1197 Page 7 of 8molecular studies of CRCs should take macroscopic sub-
types into consideration and highlight the importance of
consensus and communication between endoscopic and
pathologic diagnosis.
Conclusion
Three different macroscopic subtypes of colorectal neo-
plasms display distinct carcinogenetic pathways in EGFR
networking. Further molecular studies of CRCs should
take macroscopic subtypes into consideration and high-
light the importance of consensus and communication
between endoscopic and pathologic diagnosis.
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